We describe a case of primary aldosteronism due to an aldosterone producing adenoma with high and non-suppressible plasma renin activity (PRA). She had suppressed PRA at initial diagnosis. This rose above the reference range for normal individuals over a period of 7 years with untreated hypertension. We discuss the
Introduction
Primary aldosteronism is classically associated with hypertension, hypokalaemia and suppressed plasma renin activity (PRA). Most cases are due to an aldosterone producing adenoma (APA). We present a case of prolonged, untreated, primary aldosteronism due to an APA. She had suppressed PRA at the time of diagnosis, which became elevated and non-suppressible by intravenous salt loading. While raised PRA has been reported previously in primary aldosteronism, 1 spontaneous rise in PRA from suppressed levels in any one patient with primary aldosteronism is unusual. We discuss the various pathophysiological processes that may have resulted in this change.
Biochemical methods
Serum aldosterone (normal range 16.6-617.7 pmol/l) was measured by radioimmunoassay (Coat-A Count Aldosterone, Diagnostic Products Corporation, Los Angeles, CA, USA). PRA (normal range 0.66-3.08 g/l/h) was assayed using radioimmunoassay (Incstar Gammacoat 1251 Plasma Renin Activity Radioimmunoassay kit, Incstar Corporation, Stillwater, MN, USA). To calculate the aldosterone/renin ratio, the serum aldosterone was first divided by 27.75 to convert the concentration from pmol/l to ng/dl before dividing by the PRA.
possible pathophysiological causes of a rise in PRA in this clinical setting and suggest that underlying arteriolar disease due to prolonged hypertension may be the cause of increased and non-suppressible PRA in primary aldosteronism.
Case report
Our patient was a 34-year-old woman who was found to have hypertension during the fifteenth week of pregnancy. Plasma aldosterone was 2039 pmol/l, PRA Ͻ0.15 g/l/h and a diagnosis of primary aldosteronism was made. Following the delivery of her child, she defaulted follow-up and was not treated with any antihypertensives nor potassium supplements.
In 1997, 7 years after the original diagnosis, she suffered a thalamic haemorrhage resulting in hemiplegia. On admission, there was marked hypertension (219/141 mm Hg) and hypokalaemia (serum K + 1.4 mmol/l). Her ECG showed marked left ventricular hypertrophy but the cardiac shadow was not enlarged on a plain chest radiograph. No hypertensive retinopathy was noted. Serum aldosterone and PRA were 2334.4 pmol/l and 3.26 g/l/h respectively. It should be noted that she was on fluid restriction and sodium was undetectable in her urine at that time. Twenty-four hour urinary catecholamines and cortisol levels were normal.
Control of her blood pressure was achieved with prazosin 5 mg (6 hourly) and nifedipine 15 mg (8 hourly). Subsequently, she was put on an intravenous infusion of 2 L of normal saline and 80 mmols of potassium daily for 3 days. Biochemical data were obtained as in Table 1 . Postural studies were not possible at the time due to the right hemiparesis.
A captopril renogram was performed which showed no evidence of renal artery stenosis. A CT scan of the abdomen revealed a 2 × 1 cm nodule in the left adrenal and normal sized kidneys. Adrenal vein sampling was performed 2 months after her intracranial bleed. The results are in Table 2 . She was subjected to laparoscopic adrenalectomy and a left adrenal cortical adenoma (confirmed on histology) was excised. Preoperatively, she required prazosin 4 mg t.i.d., nifedipine 20 mg q.i.d., atenolol 100 mg o.m. and spironolactone 100 mg t.i.d. for blood pressure control. Despite this treatment, she continued to have hypokalaemia requiring oral potassium supplementation of 78 mmol per day. During this period, captopril was briefly added to her treatment regimen for poorly controlled blood pressure and hypokalaemia. This resulted in an acute deterioration in renal function (serum creatinine rose from 93 mol/l to 202 mol/l) which resolved after withdrawal of the drug. Postoperatively, her blood pressure is controlled on atenolol 100 mg om and Adalat LA 30 mg o.m. Her serum potassium is now normal (4.8 mmol/l) without supplementation. Repeat PRA was 0.52 g/l/hour and serum aldosterone was 308.8 pmol/l.
Discussion
There is little doubt that this patient had primary aldosteronism at the time of her initial presentation given the presence of hypertension, hypokalaemia, very high levels of serum aldosterone and PRA suppressed below the limits of the assay. Even allowing for the rise in plasma aldosterone during normal pregnancy, the value of 2039 pmol/l exceeds the levels expected in the first trimester although it could be considered normal in the third trimester. Furthermore, the increase in plasma aldosterone during pregnancy is correlated with an increase in the PRA rather than suppression as seen in this case. 2 Primary aldosteronism is confirmed again by failure of suppression of the 24-h urine aldosterone excretion below 14 g/day, 1 which is perhaps the most sensitive test for primary aldosteronism. There are several unusual features about this case. This patient presented during pregnancy with hypertension and hypokalaemia when we know that patients with primary aldosteronism often become normotensive and normokalaemic during pregnancy due to the spironolactone-like effect of progesterone. Perhaps of greater interest is the finding that the PRA, having been suppressed early in the course of the disease has spontaneously risen to levels above the reference range, even following salt loading. Non-suppressed PRA is not in itself an unusual finding in primary aldosteronism. Bravo et al 1 found that 12.5% of patients with primary aldosteronism had normal PRA and 15% had PRA above the 95% confidence intervals for normal individuals of the population. However, the lack of suppression of PRA in these individuals has never been fully explained and a rise in PRA from suppressed levels to above the normal range have not been described in the same patient.
There are several pathophysiological reasons why the PRA may have risen. Fluid and salt restriction could cause high PRA.
3 This is the basis of diagnostic tests using the PRA after salt depletion for the diagnosis of primary aldosteronism. Although PRA usually does not exceed 2 ng/ml/h following salt depletion in primary aldosteronism, 4 it does occur in 36% of patients. The PRA was even higher in the salt replete state and this is unusual. We believe the salt load was adequate as the 24-h urinary sodium was 260 mmol/l and took place 4 days after the fluid restriction was lifted. We therefore do not feel that salt or fluid depletion was responsible for the hyperreninaemia seen in this patient. Other causes of renal hypoperfusion such as cardiac failure, liver cirrhosis or nephrotic syndrome were not evident. This patient did not exhibit any oedema or hypoalbuminaemia to suggest nephrotic syndrome.
Drugs can give rise to hyperreninaemia and these would include the angiotensin-converting enzyme inhibitors, the aldosterone antagonist spironolactone, or angiotensin II receptor antagonists. None of these agents were used in this patient. The calcium channel blockers can raise PRA in normal individuals. This occurs through inhibition of calcium entry into juxtaglomerular apparatus cells resulting in renin release. Although this patient was on nifedipine at this time, we do not feel this is sufficient to explain all the current findings.
Hyperreninaemic hypertension has been reported in association with acute pyelonephritis, 5 unilateral hydronephrosis [6] [7] [8] and blunt trauma to the kidney. 9, 10 It has also been reported following haemorrhage into the perinephric space from polycystic kidney disease. 11 None of these conditions were evident in this patient.
This brings us to various vascular causes of hyperreninaemic hypertension. This can be due to decreased renal perfusion as in renal artery sternosis 12 or dissecting aneurysm of the renal artery. 13, 14 Involvement of smaller vessels by systemic sclerosis 15, 16 and necrotising vasculitis 17 can also cause hyperreninaemia but these were not evident in this case. Malignant hypertension gives rise to hyperreninaemia and this has been reported in patients with aldosterone producing adenomas.
We have to entertain this possibility despite the absence of any retinal changes to suggest malignant hypertension as Beevers et al 19 noted the absence of these signs in two of four patients who exhibited fibrinoid necrosis on renal biopsy. We do not have a renal biopsy from this patient. However, there was no haematuria on urine microscopy, which often accompanies fibrinoid necrosis. Finally, arteriolar damage from hypertensive nephrosclerosis can give rise to high PRA. When we examine the results of the adrenal vein sampling, the extremely high aldosterone concentration in the left adrenal vein and a ratio of aldosterone from the left adrenal vein to aldosterone in the inferior vena cava of 23.22 (Ͼ10) suggests a left adrenal adenoma, 20 even though the right adrenal vein was not cannulated successfully. Despite this, the aldosterone secretion from the right adrenal is clearly unsuppressed as the level of aldosterone in the blood taken from around the right adrenal vein is higher than surrounding areas reflecting activation of the renin angiotensin system similar to that seen in unilateral renal artery stenosis. The same results can occur in hypertensive nephrosclerosis and Pettinger et al 21 have used the term pseudo renal artery stenosis to describe this occurrence on a background of hypertensive nephrosclerosis.
We feel that hypertensive nephrosclerosis has resulted in the rise in PRA in this patient over a 7-year period of untreated hypertension. Underlying renal arteriolar disease is suggested by the acute, reversible deterioration in renal function caused by captopril. This can occur in bilateral renal artery stenosis, renal artery stenosis to a single kidney or in those with severe arteriolar disease. 21, 22 This patient had a normal captopril renogram, which although is not the gold standard for diagnosis of renal artery stenosis (sensitivity 71-92%, [23] [24] [25] [26] ), makes this diagnosis unlikely.
We would not be surprised that she has significant hypertensive nephrosclerosis. Conn's original description of a case of aldosterone producing adenoma included the finding of severe arteriosclerosis in the renal biopsies. 27 The development of renal vascular complications has been found to be as common in hyperaldosteronism as in other causes of hypertension. 19 The extent of end-organ damage (left ventricular hypertrophy on her ECG and haemorrhagic stroke) would be consistent with the presence of renal damage from prolonged hypertension.
Good blood pressure control could explain the suppression of the PRA after treatment. The use of atenolol in the management of this patient's hypertension can also lower PRA. 28 In a previous report of malignant hypertension with high PRA and aldsterone producing adenoma, a lowering of PRA to similar levels by drug treatment was also seen. 18 The diagnosis of primary aldosteronism has been fraught with controversy with regards the ideal diagnostic test. 29 Tests that utilise PRA include PRA after salt depletion 4 and the plasma aldosterone to renin ratio. 30, 31 Both of these tests fail to establish the diagnosis in this case due to the high PRA before and after salt loading and the aldosterone/renin ratio of only 7.9, which is well below the suggested cutoff of 50. We would like to suggest that a rise in the PRA might be part of the natural history of primary aldosteronism. This may be due to prolonged hypertension resulting in arteriolar disease or hypertensive nephrosclerosis. This could be the reason why diagnostic tests, which include suppression of the PRA, often fail to diagnose primary aldosteronism. The development of hypertensive nephrosclerosis resulting in hyperreninaemia may also explain the observation that higher PRA is associated with a lower cure rate after adrenal surgery in patients with aldosterone producing adenoma. 30 Although primary aldosteronism is an uncommon cause of hypertension (1%), it is an important diagnosis to make as it is potentially curable by surgery (35-68%) 30, [32] [33] [34] [35] if due to an aldosterone producing adenoma or primary adrenal hyperplasia. Even if the cause is idiopathic hyperaldosteronism, there is a need for a rational approach to therapy, based on the underlying pathophysiology of the disease, which may differ from the usual management of essential hypertension. Surgical treatment has been beneficial in this case, even at this stage of the disease, in that blood pressure, which was poorly controlled on four drugs preoperatively, is now controlled on two and the patient no longer requires potassium supplementation.
Conclusion
This case demonstrates a spontaneous rise in PRA in primary aldosteronism caused by an aldosterone producing adenoma. This rise is probably due to the development of hypertensive nephrosclerosis secondary to prolonged hypertension. The authors feel that this may be part of the natural history of primary aldosteronism and gives rise to the lack of sensitivity of diagnostic tests that utilise PRA.
